Freelite® included in the new Monoclonal Gammopathy of Undetermined Significance (MGUS) International Guidelines
The International Myeloma Working Group has recently published guidelines on the management of monoclonal gammopathy of undetermined significance. This important consensus of 26 world experts in myeloma, states that Freelite® should be used to risk stratify MGUS patients. Some 3-4% of the population over the age of 50 are thought to have MGUS, a precursor to multiple myeloma, with about 1% per year progressing to Multiple Myeloma or other B cell dyscrasia.
Freelite® assays are manufactured and sold by Binding Site to measure free kappa and free lambda immunoglobulin light chains in serum. These quantifiable, highly specific, automatable free light chain assays are already included in international guidelines for the diagnosis, prognosis and monitoring of multiple myeloma patients.
Paul Duncan, Group Sales and Marketing Director of Binding Site said:
“Now Freelite® can help to reassure up to 40% of MGUS patients that they are unlikely to ever progress to multiple myeloma“
For more information log onto www.bindingsite.com or talk to your local Binding Site representative.